Ademi LLP is investigating Arcosa (NYSE: ACA) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with CRH.
Arcosa shareholders will receive $150 per share in an all-cash transaction valued at approximately $8.5 billion. Arcosa insiders will receive substantial benefits as part of change of control arrangements.
The transaction agreement unreasonably limits competing transactions for Arcosa by imposing a significant penalty if Arcosa accepts a competing bid. We are investigating the conduct of the Arcosa board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
Join this Action